Investors are paying attention to genetic testing stocks. What is genetic testing?

Genetic testing can detect changes in genes, chromosomes and proteins. A genetic test can be used to confirm or rule out a potential genetic condition, or help determine the likelihood of a patient developing or passing on a particular genetic disorder.

There are thousands of genetic tests available, and more are being developed.

The US National Library of Medicine lists three types of genetic tests: molecular genetic testing, which examines genes and short lengths of the DNA to identify mutations that lead to genetic disorders; chromosomal gene tests, which examine the entire genome or long lengths of the DNA to find major genetic changes; biochemical genetic tests which assess the levels of active proteins and look for irregularities that can cause genetic disorders.

Genetic testing opens the door to personalized medicine for patients. These medicines are not for investors who don't know what the term means. They focus on early diagnosis and treatment of diseases, rather than reacting to them later.

Global Market Insights estimates that genetic testing will grow to be a major market in the future. It has released a report on the potential growth of the industry. This project represents a compound annual growth rate (11.6%) between 2020-2027.

Top genetic testing stocks

Based on data from TradingView's stock screener, The 11 Ways to Make Money compiled a list containing the top genetic testing stocks that have market caps between US$2.5 and US$20 Billion. This top list of genetic testing stocks includes companies that create, market and sell diagnostic and genetic test and system products and services.

1. 10x Genomics (NASDAQ :TXG).

Market Cap: US$18.712 Billion

Our top genetics stocks include 10x Genomics, which is a biotechnology company that designs and manufactures gene-sequencing technology for scientific research. This health technology blends hardware, chemistry, and software to give single-cell and spatial views of biological systems at high resolution and scale. More than 1,150 patent applications and issued patents are part of the company's patent portfolio.

10x Genomics is a company that targets a wide range of health areas, including oncology, immunology, and neuroscience. With the recent opening in Singapore of its manufacturing facility and commercial hub, 10x Genomics is expanding geographically. Serge Saxonov (co-founder and CEO) stated that Singapore is a world hub for biotechnology and has a strong research community.

2. Exact Sciences (NASDAQ :EXAS).

Market Cap: US$16.24 Billion

Exact Sciences is a molecular diagnostic test company. Genomic Health was acquired by Exact Sciences in 2019. The company developed Coleguard, a molecular screening platform that detects various cancers.

Coleguard may indicate advanced adenoma or colorectal carcinoma. This means that a diagnostic colonoscopy is necessary to confirm the diagnosis. Coleguard is designed for patients over 50 with a high risk of developing colorectal cancer. Exact Sciences also offers the Oncotype DX test to detect breast cancer recurrence.

3. Guardent Health (NASDAQ:GH)

Market Cap: US$11.428 Billion

Guardent Health is next on the list of top genetic testing stocks. This precision oncology company offers proprietary blood tests, large data sets, and advanced analytics. Guardant360 CDx is one of the company's products. This allows oncologists to get comprehensive genomic results in just one week, allowing them to match patients with the best treatment plan.

Guardent Health is currently working on a blood test that will screen patients at average risk for colorectal carcinoma (CRC). This test will help identify patients with early-stage CRC. "We know that CRC can be detected earlier, which increases the chance of someone surviving it," stated Dr. Heecheol Kim, a study investigator and professor at the Samsung Medical Center in Seoul.

4. Natera (NASDAQ:NTRA)

Market Cap: US$10.89 Billion

Natera, a company that specializes in genetic testing and diagnostics, is currently developing non-invasive methods to analyze DNA. It has developed 10 molecular screening tools over the past 10 years. The laboratory also performs thousands of genetic tests every month.

Natera's main areas of interest are women's health via reproduction health, organ transplantation, and cancer. Its cloud-based software platform allows it to offer genetic testing services that are designed to educate biopharmaceutical companies researchers as well as other healthcare professionals who treat and test pregnant women.

5. Invitae (NYSE :NVTA).

Market Cap: US$6.042 Billion

Invitae, a genetics information company, advocates for personalized medicine and treatments that are more specific.

The firm is a specialist in genetic diagnostics. It has a portfolio that includes software tools and lab processes, genetic testing, and analysis. Invitae offers diagnostic tests for genetic disorders, metabolic conditions, genetic disorders, and pediatric and developmental problems. It also provides preimplantation screening and miscarriage analysis.

Securities Disclosure - I, Melissa Pistilli have no direct investment in any company mentioned.

By: Melissa Pistilli
Title: 5 Top Genetic Testing Stocks
Sourced From: investingnews.com/daily/life-science-investing/genetics-investing/top-genetic-testing-stocks/
Published Date: Wed, 03 Nov 2021 20:15:15 +0000

-----------------------------